Clinical trials: Hepatic Malignancies
Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
This phase II trial studies the efficacy and safety of systemic induction of mFOLFIRINOX, followed by hepatic arterial infusion (HAI) floxuridine-dexamethasone administered concurrently with systemic mFOLFIRI in treating patients…
- Conditions
- Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT04251715
- Testing
- Dexamethasone, Floxuridine, Implanted Medical Device
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Liver Metastases, Colorectal Cancer Metastatic
Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation
The COLT trial is an investigator-driven, multicenter, non-randomized, open-label, controlled, prospective, parallel trial, aimed at assessing the efficacy (in terms of overall survival: OS) of liver transplantation (LT) in…
- Conditions
- Liver Metastases, Colorectal Cancer Metastatic, Liver Neoplasm, Neoplasms
- Trial name
- COLT (NCT03803436)
- Testing
- Liver transplant, Chemotherapy
- Where
- 12 sites in Italy
- Volunteers
- 38 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Hepatocellular Carcinoma, Portal Hypertension
CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)
This study aims to evaluate the impact of non-invasive CT-based Hepatic Venous Pressure Gradient (HVPG) assessment on prognosis of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE).
- Trial name
- NCT05704192
- Testing
- TACE ± Systemic therapy
- Where
- 2 sites in China
- Volunteers
- 373 people
- Sponsor
- Zhongda Hospital
HCC, Portal Vein Tumor Thrombosis
ISP-TACE Versus TACE for HCC With PVTT
For patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT), the survival benefit of transarterial chemoembolization (TACE) remains modest.
- Trial name
- NCT03108248
- Testing
- ethiodized oil; doxorubicin;Gelfoam;, stent; idoine-125
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Zhongda Hospital
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Among resectable biliary tract cancers (BTC) patients, surgery has historically been the standard treatment, but even with curative surgery, the cure rates remain relatively low, with most patients relapsing in the short term and…
- Trial name
- NCT06739252
- Testing
- Gemcitabine Oxaliplatin and 5FU
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Peking University
Pancreatic Adenocarcinoma, Liver Metastases
Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
This is a single arm, phase II study without blinding. The purpose is to determine the impact of hepatic artery infusion Floxuridine (FUDR) on liver metastases from pancreatic adenocarcinoma.
- Trial name
- NCT03856658
- Testing
- Floxuridine (FUDR), Hepatic Artery Infusion Pump, Heparinized Saline
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Corewell Health West
Liver Neoplasms
TheraSphere Japan Pre-Market Study
To investigate the safety and effectiveness of BSJ019T in Japanese patients with primary or secondary liver who are not candidate for standard treatment.
- Trial name
- INDIGO (NCT07377487)
- Testing
- TheraSphere Y-90 glass microsphere
- Where
- 5 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Boston Scientific Corporation
Pancreatic Neoplasms, Hepatic Metastasis of Pancreatic Cancer
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
This Phase II clinical study evaluates the safety and efficacy of a combination therapy for patients with pancreatic cancer that has spread to the liver.
- Trial name
- NCT07504471
- Testing
- pH-NASOX-Immune Group
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Hepatic Neoplasms
Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method
Blood loss during liver resection significantly associates with short term operative outcome. The median blood loss during partial liver resection is 700-1200ml in high-volume centers.
- Trial name
- NCT02213692
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Hui-Chuan Sun
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients
This study is working to evaluate the surgical comprehensive treatment for different types of tumor thrombi in the portal vein for hepatocellular carcinoma patients, to establish a standardized, unified, effective therapeutic…
- Trial name
- NCT00849264
- Testing
- chemotherapy with endostar, treatment with CBP and 5-FU, treatment with endostar, CBP and 5-FU
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Cancer, Metastatic Cancer
Quality of Life in Patients With Liver Cancer Treated With Image-Guided Therapy
RATIONALE: Gathering information about quality of life over time from patients with liver cancer treated with image-guided therapy may help the study of cancer in the future.
- Trial name
- NCT00482586
- Testing
- medical chart review, questionnaire administration, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 137 people
- Sponsor
- Vanderbilt University
Neoplasms, Colorectal
A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases
The primary purpose of this study is to determine the safety and tolerability of SRT501 (5.0 g) in subjects with colorectal cancer and hepatic metastases when administered once daily for 14 days.
- Trial name
- NCT00920803
- Testing
- SRT501
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- Sirtris, a GSK Company
Colorectal Neoplasms
FOLFOXIRI-based HAIC Combined With Fuquintinib as Late-line Treatment in Patients With CRLM：A Phase 2 Single-Arm Clinical Trial
This study was a phase 2, single-arm, single-center clinical trial in which previously treated patients with unresectable colorectal cancer liver metastases.
- Trial name
- HAIC，CRLM (NCT07024537)
- Testing
- FOLFOXIRI-based HAIC+Fuquinitinib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Meng Qiu
Hepatocellular Carcinoma, Liver Cancer
Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma
Rationale: Patients diagnosed with hepatocellular carcinoma (HCC) at an intermediate or advanced stage (according to the BCLC classification system) are not amenable of curative treatment.
- Trial name
- NCT00910572
- Testing
- Yttrium-90 microspheres (Therasphere MDS Nordion)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Hemangioma
Fluctuational Imaging for the Diagnosis of Hepatic Hemangioma: A Multicenter, Prospective Study
[Background and Rationale] Hepatic hemangioma is the most common benign tumor of the liver, with a reported prevalence of up to 20% in the general population.
- Trial name
- NCT07418294
- Where
- South Korea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Hepatocellular Carcinoma
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with hepatocellular…
- Trial name
- NCT03468231
- Testing
- Sorafenib, HAIC of FOLFOX, HAIC of OXA
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Hepatic Impairment
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
This is a phase I, multi-center, open-label, single oral dose, parallel group study to evaluate the pharmacokinetics and safety of INC280 in non-cancer subjects with impaired hepatic function and non-cancer subjects with normal…
- Trial name
- NCT02474537
- Testing
- INC280
- Where
- 5 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Advanced Adult Primary Liver Cancer
Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE
To investigate the therapy effect and security of oxaliplatin and fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
- Trial name
- NCT02557503
- Testing
- Oxaliplatin and fluorouracil
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhu Xu
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.